SCHEMBL360304

SCHEMBL360304

COc1cnc2ccc(Br)cc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.54
F2 P00734 1/20 0.54
GLA P06280 1/20 0.54
PDGFRB P09619 5/20 0.50
PDGFRA P16234 5/20 0.50
EGFR P00533 3/20 0.49
MALT1 Q9UDY8 1/20 0.45
NPM1 P06748 1/20 0.43
ALK Q9UM73 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KCNH2 Q12809 1/20 0.40
FLT3 P36888 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 2/20 0.40
USP2 O75604 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL621672 0.86 PDGFRB (0.58) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL4543031 0.86 HPGDS (0.47) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL7028923 0.85 ALDH1A1 (0.70) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL25216330 0.84 PDGFRB (0.53) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL31052346 0.84 PDGFRB (0.53) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL163368 0.83 SLC2A1 (0.42) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL187431 0.82 FBP1 (0.44) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL15041953 0.80 ALDH1A1 (0.55) ALDH1A1HPGDF2GLAPDGFRB
SCHEMBL21988640 0.79 ALDH1A1 (0.71) ALDH1A1HPGDF2GLAMALT1
SCHEMBL620427 0.79 ALDH1A1 (0.54) ALDH1A1HPGDF2GLAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3569596-A1 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Jiangsu Hengrui Medicine Co. Ltd. (CN) 2019-11-20 EP disclosed
EP-2307400-B1 INHIBITORS OF PI3 KINASE AMGEN INC (US) 2014-04-23 EP disclosed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET ALDH1A1 762/4885HPGD 2605/4885F2 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.